Conversion surgery after chemoimmunotherapy for esophageal squamous cell carcinoma with gastric intramural metastasis: a case report and the literature review.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
three cycles of combination immunochemotherapy with cisplatin, 5-fluorouracil, and pembrolizumab
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The patient remains recurrence-free 8 months postoperatively. Further studies are warranted to clarify the optimal criteria for assessing ICI treatment response and determining indications for conversion surgery in such cases.
Immune checkpoint inhibitors (ICIs) have recently emerged as promising first-line treatments.
APA
Kitano Y, Sugawara K, et al. (2026). Conversion surgery after chemoimmunotherapy for esophageal squamous cell carcinoma with gastric intramural metastasis: a case report and the literature review.. Journal of surgical case reports, 2026(2), rjag073. https://doi.org/10.1093/jscr/rjag073
MLA
Kitano Y, et al.. "Conversion surgery after chemoimmunotherapy for esophageal squamous cell carcinoma with gastric intramural metastasis: a case report and the literature review.." Journal of surgical case reports, vol. 2026, no. 2, 2026, pp. rjag073.
PMID
41710055 ↗
Abstract 한글 요약
Immune checkpoint inhibitors (ICIs) have recently emerged as promising first-line treatments. Among stage IVb esophageal squamous cell carcinoma (ESCC) cases, gastric wall metastasis is rare, and conversion surgery after ICI therapy in such cases is extremely uncommon. We report a case of stage IVb ESCC with gastric intramural metastasis (IM) successfully treated with conversion surgery following ICI-based chemoimmunotherapy, along with a review of the relevant literature. A 73-year-old man was diagnosed with ESCC with gastric IM (Mt, SCC, cT3brN1M1b [IM-St], stage IVb). He received three cycles of combination immunochemotherapy with cisplatin, 5-fluorouracil, and pembrolizumab. Conversion surgery was subsequently performed. Pathological examination demonstrated a complete response, with no residual carcinoma in either the esophagus or the gastric wall. The patient remains recurrence-free 8 months postoperatively. Further studies are warranted to clarify the optimal criteria for assessing ICI treatment response and determining indications for conversion surgery in such cases.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Prognostic significance of fibroblast senescence and senescence-associated secretory phenotype factor expression in the tumor microenvironment of pancreatic ductal adenocarcinoma.
- Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT.
- Response to the comment on "Subcutaneous/cutaneous uptake in the cancer-affected breast on F-FDG PET/CT: association with post-surgical prognosis in breast cancer patients".
- Response to the comment on "Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT".
- Subcutaneous/cutaneous uptake in the cancer-affected breast on F-FDG PET/CT: association with post-surgical prognosis in breast cancer patients.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.